Treatment of recurrent cervical adenocarcinoma with BMS-247550, an epothilone B analog.
Gynecol Oncol
; 90(1): 96-9, 2003 Jul.
Article
em En
| MEDLINE
| ID: mdl-12821348
ABSTRACT
OBJECTIVE:
The incidence of recurrent cervical adenocarcinoma is rising relative to the squamous subtype. There are limited therapeutic options for women with advanced cervical adenocarcinoma. Only a few chemotherapy agents have demonstrated activity in this disease. This report describes results with BMS-247550, an epothilone B analog that stabilizes microtubules, with activity in previously treated adenocarcinoma of the cervix.METHOD:
We present two women with recurrent cervical adenocarcinoma with metastases to the lung. Both women were treated previously with paclitaxel and were enrolled in a phase I study with BMS-247550. Both women had partial responses to BMS-247550 with a decrease in tumor size and CA-125 levels.CONCLUSIONS:
The demonstration of a response to BMS-247550, especially after additional chemotherapy had been administered, is encouraging, albeit preliminary. The ultimate role of BMS-247550 and multiagent chemotherapy in the treatment of adenocarcinoma of the cervix should be further investigated.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Adenocarcinoma
/
Neoplasias do Colo do Útero
/
Epotilonas
/
Recidiva Local de Neoplasia
/
Antineoplásicos
Limite:
Adult
/
Female
/
Humans
/
Middle aged
Idioma:
En
Ano de publicação:
2003
Tipo de documento:
Article